Related Experiment Video
Updated: Jan 30, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia
Rong Chen1, Mingzhao Zhu2,3, Rajan R Chaudhari1
1Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Abstract:
The viability of chronic lymphocytic leukemia (CLL) is critically dependent upon staving off death by apoptosis, a hallmark of CLL pathophysiology. The recognition that Mcl-1, a major component of the anti-apoptotic response, is intrinsically short-lived and must be continually resynthesized suggested a novel therapeutic approach. Pateamine A (PatA), a macrolide marine natural product, inhibits cap-dependent translation by binding to the initiation factor eIF4A. In this study, we demonstrated that a synthetic derivative of PatA, des-methyl des-amino PatA (DMDAPatA), blocked mRNA translation, reduced Mcl-1 protein and initiated apoptosis in CLL cells. This action was synergistic with the Bcl-2 antagonist ABT-199. However, avid binding to human plasma proteins limited DMDAPatA potency, precluding further development. To address this, we synthesized a new series of PatA analogs and identified three new leads with potent inhibition of translation. They exhibited less plasma protein binding and increased cytotoxic potency toward CLL cells than DMDAPatA, with greater selectivity towards CLL cells over normal lymphocytes. Computer modeling analysis correlated their structure-activity relationships and suggested that these compounds may act by stabilizing the closed conformation of eIF4A. Thus, these novel PatA analogs hold promise for application to cancers within the appropriate biological context, such as CLL.
Insights
Novel Pateamine A analogs effectively target chronic lymphocytic leukemia (CLL) by inhibiting protein synthesis and inducing cancer cell death. These compounds show promise for developing new CLL therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Chronic lymphocytic leukemia (CLL) cell survival relies on inhibiting apoptosis.
- Mcl-1 protein is crucial for anti-apoptotic response in CLL and requires continuous synthesis.
- Pateamine A (PatA) is a natural product that inhibits cap-dependent translation via eIF4A.
Purpose of the Study:
- To investigate the therapeutic potential of PatA derivatives against CLL.
- To develop novel PatA analogs with improved potency and selectivity for CLL treatment.
Main Methods:
- Synthesis and evaluation of a PatA derivative, des-methyl des-amino PatA (DMDAPatA).
- Assessment of DMDAPatA's effects on mRNA translation, Mcl-1 levels, and apoptosis in CLL cells.
- Synergistic studies with the Bcl-2 antagonist ABT-199.
- Development and characterization of new PatA analogs.
- Computer modeling for structure-activity relationship analysis.
Main Results:
- DMDAPatA inhibited mRNA translation, reduced Mcl-1, and induced apoptosis in CLL cells, showing synergy with ABT-199.
- High plasma protein binding limited DMDAPatA's potency.
- Novel PatA analogs demonstrated potent translation inhibition with reduced plasma protein binding.
- New analogs showed increased cytotoxicity towards CLL cells and better selectivity over normal lymphocytes.
Conclusions:
- Novel PatA analogs are potent inhibitors of translation and exhibit promising anti-CLL activity.
- These analogs overcome limitations of previous derivatives, offering improved therapeutic potential.
- The developed compounds may be valuable for treating cancers like CLL.
More Related Videos
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
11:39Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
Related Concept Videos
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
01:31Translation
Translation Produces the Building Blocks of Life
Proteins are...
02:33Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
01:44Termination of Translation
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:27Post-translational Translocation of Proteins to the RER
Targeting proteins to the ER
Hsp40 and Hsp70 chaperone molecules bind the translated proteins in the cytosol to prevent their folding. The chaperone binding helps to keep the signal...